Paola Vázquez-Cárdenas

Dr. Paola Vázquez-Cárdenas

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2012 in Diabetes
Verified
Journal Article
Open access
PDF file
MGMarco Alberto Gamboa-Meléndez
Marco Alberto Gamboa-Meléndez
AHAlicia Huerta-Chagoya
Alicia Huerta-Chagoya
HMHortensia Moreno-Macías
Hortensia Moreno-Macías
PVPaola Vázquez-Cárdenas
Paola Vázquez-Cárdenas
MOMaría Luisa Ordóñez-Sánchez
María Luisa Ordóñez-Sánchez
TTTeresa Tusié-Luna
Teresa Tusié-Luna
Several studies have identified nearly 40 different type 2 diabetes susceptibility loci, mainly in European populations, but few of them have been evaluated in the Mexican population. The aim of this study was to examine the extent to which 24 common genetic variants previously associated with type 2 diabetes are associated in Mexican Mestizos. Twenty-four single nucleotide polymorphisms (SNPs) in or near genes (KCNJ11, PPARG, TCF7L2, SLC30A8, HHEX, CDKN2A/2B, CDKAL1, IGF2BP2, ARHGEF11, JAZF1, CDC123/CAMK1D, FTO, TSPAN8/LGR5, KCNQ1, THADA, ADAMTS9, NOTCH2, NXPH1, RORA, UBQLNL, and RALGPS2) were genotyped in Mexican Mestizos. A case-control association study comprising 1,027 type 2 diabetic individuals and 990 control individuals was conducted. To account for population stratification, a panel of 104 ancestry-informative markers was analyzed. Association to type 2 diabetes was found for rs13266634 (SLC30A8), rs7923837 (HHEX), rs10811661 (CDKN2A/2B), rs4402960 (IGF2BP2), rs12779790 (CDC123/CAMK1D), and rs2237892 (KCNQ1). In addition, rs7754840 (CDKAL1) was associated in the nonobese type 2 diabetic subgroup, and for rs7903146 (TCF7L2), association was observed for early-onset type 2 diabetes. Lack of association for the rest of the variants may have resulted from insufficient power to detect smaller allele effects.

18 July 2017 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
EMErnesto Miranda-Morales
Ernesto Miranda-Morales
KMKarin Meier
Karin Meier
ASAda A. Sandoval-Carrillo
Ada A. Sandoval-Carrillo
JSJosé M. Salas-Pacheco
José M. Salas-Pacheco
PVPaola Vázquez-Cárdenas
Paola Vázquez-Cárdenas
Oscar Arias-CarriónOscar Arias-Carrión
Oscar Arias-Carrión
It has been 200 years since Parkinson´s disease (PD) was first described, yet many aspects of its etiopathogenesis remain unclear. PD is a progressive and complex neurodegenerative disorder caused by genetic and environmental factors including aging, nutrition, pesticides and exposure to heavy metals. DNA methylation may be altered in response to some of these factors; therefore, it is proposed that epigenetic mechanisms, particularly DNA methylation, can have a fundamental role in gene-environment interactions that are related with PD. Epigenetic changes in PD-associated genes are now widely studied in different populations, to discover the mechanisms that contribute to disease development and identify novel biomarkers for early diagnosis and future pharmacological treatment. While initial studies sought to find associations between promoter DNA methylation and the regulation of associated genes in PD brain tissue, more recent studies have described concordant DNA methylation patterns between blood and brain tissue DNA. These data justify the use of peripheral blood samples instead of brain tissue for epigenetic studies. Here, we summarize the current data about DNA methylation changes in PD and discuss the potential of DNA methylation as a potental biomarker for PD. Additionally, we discuss environmental and nutritional factors that have been implicated in DNA methylation. Although the search for significant DNA methylation changes and gene expression analyses of PD-associated genes have yielded inconsistent and contradictory results, epigenetic modifications remain under investigation for their potential to reveal the link between environmental risk factors and the development of PD.

14 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AHAlicia Huerta-Chagoya
Alicia Huerta-Chagoya
PVPaola Vázquez-Cárdenas
Paola Vázquez-Cárdenas
HMHortensia Moreno-Macías
Hortensia Moreno-Macías
LTLeonardo Tapia-Maruri
Leonardo Tapia-Maruri
RRRosario Rodríguez-Guillén
Rosario Rodríguez-Guillén
TTTeresa Tusié-Luna
Teresa Tusié-Luna
Epidemiological and physiological similarities among Gestational Diabetes Mellitus (GDM) and Type 2 Diabetes (T2D) suggest that both diseases, share a common genetic background. T2D risk variants have been associated to GDM susceptibility. However, the genetic architecture of GDM is not yet completely understood. We analyzed 176 SNPs for 115 loci previously associated to T2D, GDM and body mass index (BMI), as well as a set of 118 Ancestry Informative Markers (AIMs), in 750 pregnant Mexican women. Association with GDM was found for two of the most frequently replicated T2D loci: a TCF7L2 haplotype (CTTC: rs7901695, rs4506565, rs7903146, rs12243326; P=2.16x10-06; OR=2.95) and a KCNQ1 haplotype (TTT: rs2237892, rs163184, rs2237897; P=1.98x10-05; OR=0.55). In addition, we found two loci associated to glycemic traits: CENTD2 (60’ OGTT glycemia: rs1552224, P=0.03727) and MTNR1B (HOMA B: rs1387153, P=0.05358). Remarkably, a major susceptibility SLC16A11 locus for T2D in Mexicans was not shown to play a role in GDM risk. The fact that two of the main T2D associated loci also contribute to the risk of developing GDM in Mexicans, confirm that both diseases share a common genetic background. However, lack of association with a Native American contribution T2D risk haplotype, SLC16A11, suggests that other genetic mechanisms may be in play for GDM.

16 June 2023 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
LMLaura E. Martínez-Gómez
Laura E. Martínez-Gómez
CMCarlos Martinez-Armenta
Carlos Martinez-Armenta
DMDaniel Medina-Luna
Daniel Medina-Luna
MOMaría Luisa Ordoñez-Sánchez
María Luisa Ordoñez-Sánchez
TTTeresa Tusié-Luna
Teresa Tusié-Luna
ALAlberto López-Reyes
Alberto López-Reyes
During a viral infection, the immune response is mediated by the toll-like response and myeloid differentiation Factor 88 (MyD88), who play an important role sensing infections such as SARS-CoV-2 who has claimed the lives of more than 6.8 million people around the world. We carried out a cross-sectional with a population of 618 SARS-CoV-2-positive unvaccinated subjects and further classified based on severity: 22% were mild, 34% were severe, 26% were critical, and 18% were deceased. Toll Like Receptor 7 (TLR7) single-nucleotide polymorphisms (rs3853839, rs179008, rs179009, and rs2302267) and MyD88 (rs7744) were genotyped using TaqMan OpenArray. The association of polymorphisms with disease outcomes was performed by logistic regression analysis adjusted by covariates. A significant association of rs3853839 and rs7744 of the TLR7 and MyD88 genes, respectively, was found with COVID-19 severity. The G/G genotype of the rs3853839 TLR7 was associated with the critical outcome showing an Odd Ratio=1.98 (95% IC= 1.04-3.77). The results highlighted an association of the G allele of MyD88 gene with severe, critical and deceased outcomes. Furthermore, in the dominant model (AG+GG vs. AA), we observed an Odd Ratio =1.70 (95% CI = 1.02-2.86) with severe, Odd Ratio = 1.82 (95% CI = 1.04-3.21) with critical, and Odd Ratio =2.44 (95% CI = 1.21-4.9) with deceased outcomes. To our knowledge this work represents an innovator report that highlights the significant association of TLR7 and MyD88 gene polymorphisms with COVID-19 outcomes and the possible implication of the MyD88 variant with D-dimer and IFN-α concentrations.

Verified
Journal Article
Open access
PDF file
TRTania Rivera-Carranza
Tania Rivera-Carranza
ALAngélica León-Téllez-Girón
Angélica León-Téllez-Girón
RGRaquel González
Raquel González
PVPaola Vázquez-Cárdenas
Paola Vázquez-Cárdenas
ACAna Laura Campos
Ana Laura Campos
RBRafael Bojalil
Rafael Bojalil
Obesity is considered a state of chronic low-grade inflammation that impacts the development of chronic degenerative diseases. Cellular immunity plays a crucial role in the onset and persistence of this inflammatory condition. As the degree of obesity increases, significant distinct immunometabolic alterations are observed compared to individuals with normal weight. Moreover, obese patients who undergo bariatric surgical procedures for weight loss exhibit changes in the proportion of immune cells. These alterations help to explain several molecular processes associated with inflammation in obesity, including protein activation and inactivation, precursor molecule synthesis, phosphorylation events, and the activation of signal transduction pathways, all of which are orchestrated by immune cells, primarily lymphocyte subpopulations. The study of the immunometabolic profile through lymphocyte subpopulations in obese patients can provide a more comprehensive and objective understanding of disease severity and the risk of developing obesity-related chronic degenerative conditions and thereby improve or propose therapeutic and novel approaches. Therefore, the objective of this narrative review is to offer an integrative perspective on the molecular and pathophysiological mechanisms through which lymphocyte populations contribute to obesity-related inflammation and how weight loss through bariatric surgical procedures may contribute to the therapeutic management of inflammation.

23 February 2024 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
MMMercedes Macías-Parra
Mercedes Macías-Parra
PVPatricia Vidal-Vázquez
Patricia Vidal-Vázquez
JRJesús Reyna-Figueroa
Jesús Reyna-Figueroa
MRMiguel Ángel Rodríguez-Weber
Miguel Ángel Rodríguez-Weber
HMHortensia Moreno-Macías
Hortensia Moreno-Macías
PVPaola Vázquez-Cárdenas
Paola Vázquez-Cárdenas
Introduction: Rotavirus-associated diarrheal diseases significantly burden healthcare systems, particularly affecting infants under five years. Both Rotarix™ (RV1) and RotaTeq™ (RV5) vaccines have been effective but have distinct application schedules and limited interchangeability data. This study aims to provide evidence on the immunogenicity, reactogenicity, and safety of mixed RV1-RV5 schedules compared to their standard counterparts.Methods: This randomized, double-blind study evaluated the non-inferiority in terms of immunogenicity of mixed rotavirus vaccine schedules compared to standard RV1 and RV5 schedules in a cohort of 1,498 healthy infants aged 6 to 10 weeks. Participants were randomly assigned to one of seven groups receiving various combinations of RV1, and RV5. Standard RV1 and RV5 schedules served as controls of immunogenicity, reactogenicity, and safety analysis. IgA antibody levels were measured from blood samples collected before the first dose and one month after the third dose. Non-inferiority was concluded if the reduction in seroresponse rate in the mixed schemes, compared to the standard highest responding scheme, did not exceed the non-inferiority margin of −0.10. Reactogenicity traits and adverse events were monitored for 30 days after each vaccination and analyzed on the entire cohort.Results: Out of the initial cohort, 1,365 infants completed the study. Immunogenicity analysis included 1,014 infants, considering IgA antibody titers ≥20 U/mL as seropositive. Mixed vaccine schedules demonstrated non-inferiority to standard schedules, with no significant differences in immunogenic response. Safety profiles were comparable across all groups, with no increased incidence of serious adverse events or intussusception.Conclusion: The study confirms that mixed rotavirus vaccine schedules are non-inferior to standard RV1 and RV5 regimens in terms of immunogenicity and safety. This finding supports the flexibility of rotavirus vaccination strategies, particularly in contexts of vaccine shortage or logistic constraints. These results contribute to the global effort to optimize rotavirus vaccination programs for broader and more effective pediatric coverage.Clinical trial registration: ClinicalTrials.gov, NCT02193061.